The urgent need to develop new therapies for treating both sensitive and especially resistant strains of Mycobacterium tuberculosis requires to return to basic research to explain the failures of existing treatments and identify new drug targets. Several well-established anti-tuberculosis agents, such as isoniazid and ethionamide are known to inhibit mycolic acid biosynthesis. As a consequence, a continuing biochemical study coupled with a molecular genetic approach into the anabolic pathway of mycolic acids should provide further fruitful leads in drug discovery in this application. Our immediate goals are to define, dissect, and characterize the mycolate synthase complex through the use of sub- cellular fractionation and solubilization of the activity; to purify individual enzymes and to assay for potential inhibitors of mycolate biosynthesis; to examine the complex mechanism of mycolic acid transport and the mode of action of known anti-tuberculosis drugs; and to synthesize novel structurally related therapeutic agents as custom designed inhibitors of mycolic acid biosynthesis with a view toward complementary structure-based design. Specifically, we shall study the pathway from Claisen-type condensation to final deposition of mycolic acids into cell wall components. The combined efforts of this highly experienced consortium should provide the means to solve some of the problems associated with drug resistance through understanding how mycolic acids are synthesized and providing highly developed enzymatic screens for inhibitors of mycolate biosynthesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI046393-02
Application #
6340740
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2000-09-01
Project End
2001-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2000
Total Cost
$114,008
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
112617480
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Amin, Anita G; Angala, Shiva K; Chatterjee, Delphi et al. (2009) Rapid screening of inhibitors of Mycobacterium tuberculosis growth using tetrazolium salts. Methods Mol Biol 465:187-201
Wang, Wenjian; Dong, Changjiang; McNeil, Michael et al. (2008) The structural basis of chain length control in Rv1086. J Mol Biol 381:129-40
Parish, Tanya; Schaeffer, Merrill; Roberts, Gretta et al. (2005) HemZ is essential for heme biosynthesis in Mycobacterium tuberculosis. Tuberculosis (Edinb) 85:197-204
Schaeffer, M L Merrill L; Carson, J D Jeffrey D; Kallender, Howard et al. (2004) Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesis. Tuberculosis (Edinb) 84:353-60
Brennan, P J (2003) Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) 83:91-7
Ma, Y; Stern, R J; Scherman, M S et al. (2001) Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother 45:1407-16
Escuyer, V E; Lety, M A; Torrelles, J B et al. (2001) The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem 276:48854-62